Other Primary Cancers Occurring After Treatment of Superficial Oesophageal Cancer
Overview
Affiliations
Background: Recent advances in endoscopic diagnosis and treatment have led to better prognosis for patients with superficial oesophageal cancer. The incidence of subsequent other primary cancer (SOPC) has become a new problem for patients who survive after treatment of superficial oesophageal cancer.
Methods: Between 1966 and 1998, 368 patients with superficial oesophageal cancer, histologically confirmed as squamous cell carcinoma after resection, were reviewed for the presence of SOPC.
Results: Among the 368 patients, 43 developed SOPC. The most frequent sites of SOPC were the stomach (11 patients) and hypopharynx (11). Subsequent cancers of the stomach and hypopharynx developed significantly more frequently in heavy smokers. The 5-year cumulative occurrence rate of subsequent cancers within the fields of endoscopy of the upper gastrointestinal tract (stomach, hypopharynx and residual oesophagus) was 15 per cent.
Conclusion: Gastric and hypopharyngeal cancers were frequently found after resection of superficial oesophageal cancer. A history of heavy smoking at the time of initial resection may be a risk factor. To make an early diagnosis of subsequent cancers, follow-up observation by upper gastrointestinal endoscopy is important after treatment of oesophageal cancer.
Du J, Bao Z, Liang T, Zhao H, Zhao J, Xu R Front Oncol. 2023; 13:1241572.
PMID: 37781208 PMC: 10540085. DOI: 10.3389/fonc.2023.1241572.
Agrawal R, Yang J, Ali S, Ghoulam E, Mutneja H, Bhurwal A Cureus. 2023; 15(6):e40526.
PMID: 37461759 PMC: 10350321. DOI: 10.7759/cureus.40526.
Toyoshima Y, Narumiya K, Kudo K, Egawa H, Hosoda K Glob Health Med. 2023; 5(1):40-46.
PMID: 36865898 PMC: 9974229. DOI: 10.35772/ghm.2022.01059.
Kanematsu K, Kudose Y, Utsunomiya D, Kubo K, Fujii Y, Kurita D BMC Cancer. 2022; 22(1):1245.
PMID: 36457081 PMC: 9716854. DOI: 10.1186/s12885-022-10345-5.
van Tilburg L, van de Ven S, Spaander M, van Kleef L, Cornelissen R, Bruno M J Cancer Res Clin Oncol. 2022; 149(5):1811-1823.
PMID: 35737094 PMC: 10097754. DOI: 10.1007/s00432-022-04103-0.